Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The São Paulo Patient is no longer HIV-free after more than 15 months off treatment, but was it a relapse or reinfection?
A next-generation implant maintained adequate drug levels for at least a year in an early study.
MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
New mRNA vaccine approach protects monkeys from HIV-like virus.
An experimental approach to protect HIV-fighting T cells has been cleared for its first human trial.
Four vaccine candidates produced antibody and T-cell immune responses in the first stages of human clinical trials.
Sofosbuvir and daclatasvir were linked to faster recovery and improved survival in studies in Iran.
Dexamethasone reduced mortality by up to a third among severely ill patients who needed supplemental oxygen or ventilators.
FDA grants emergency use authorization, but randomized clinical trials of the antiviral drug show mixed results.
Drugs used for decades to treat malaria may help people with the new coronavirus, but clinical trials are needed.
The protease inhibitor combination did not work significantly better than supportive care, though those treated earlier might benefit.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.